FrancophonIA/ELRC3.0 huggingface dataset:
English: In clinical trials, tumour haemorrhage was reported in approximately 2% of patients with GIST.
Croatian: U kliničkim je ispitivanjima tumorsko krvarenje prijavljeno u približno 2% bolesnika s GIST-om.
English: Treatment-related venous thromboembolic events were reported in patients who received sunitinib including deep venous thrombosis and pulmonary embolism (see section 4.8).
Croatian: Venski tromboembolijski događaji povezani s liječenjem prijavljeni su u bolesnikakoji su primali sunitinib, uključujući duboku vensku trombozu i plućnu emboliju (vidjeti dio 4.8).
English: Results for ORR are given as percent of subjects with confirmed response with the 95% CI.
Croatian: d ORR (stopa objektivnog odgovora, engl. objective response rate) rezultati su prikazani kao postotak ispitanika kod kojih je potvrđen odgovor s intervalom pouzdanosti (CI) od 95%.
English: Your doctor should do blood tests to check your liver function before and during treatment with Sutent, and as clinically indicated.
Croatian: Liječnik Vam mora provoditi pretrage krvi kako bi provjerio rad jetre prije i za vrijeme liječenja lijekom Sutent te prema kliničkoj potrebi.
English: In addition, patients should be observed closely for signs and symptoms of thyroid dysfunction during treatment, and patients who develop any signs and/or symptoms suggestive of thyroid dysfunction should have laboratory testing of thyroid function performed as clinically indicated.
Croatian: Osim toga, bolesnike se tijekom liječenja mora pomno nadzirati kako bi se uočili znakovi i simptomi disfunkcije štitnjače, a u onih bolesnika u kojih se pojave znakovi i/ili simptomi koji ukazuju na disfunkciju štitnjače treba provesti laboratorijske testove funkcije štitnjače sukladno kliničkoj potrebi.
English: No cases with fatal outcome were reported in GIST, MRCC, and pNET registrational studies.
Croatian: U registracijskim kliničkim ispitivanjima GIST-a, MRCC-a i pNET-a nije zabilježen niti jedan slučaj sa smrtnim ishodom.
English: Quartile (95% CI)
Croatian: Kvartila (95% CI)
English: The long-term safety of sunitinib in patients with MRCC was analysed across 9 completed clinical studies conducted in the first-line, bevacizumab-refractory, and cytokine-refractory treatment settings in 5,739 patients, of whom 807 (14%) were treated for ≥ 2 years up to 6 years.
Croatian: Dugoročna sigurnost sunitiniba analizirana je između 9 dovršenih kliničkih ispitivanja provedenih u 5739 bolesnika s MRCC-om refraktornim na citokine, refraktornim na bevacizumab ili sa sunitinibom kao prvom linijom liječenja, od kojih je njih 807 (14%) liječeno ≥2 godine do 6 godina.
English: There is limited clinical experience regarding the timing of reinitiation of therapy following major surgical intervention.
Croatian: Ograničeno je kliničko iskustvo što se tiče vremena koje treba proteći od velikog kirurškog zahvata do ponovnog započinjanja liječenja.
English: How to store Sutent
Croatian: Kako čuvati Sutent
English: • Nose bleeding.
Croatian: • Krvarenje iz nosa.
English: Treatment may be resumed once hypertension is appropriately controlled (see section 4.8).
Croatian: Liječenje se može nastaviti tek nakon što se hipertenzija stavi pod kontrolu (vidjeti dio 4.8).
English: Supportive care for gastrointestinal adverse reactions requiring treatment may include medicinal products with antiemetic, antidiarrhoeal, or antacid properties.
Croatian: Ako gastrointestinalne nuspojave zahtijevaju liječenje, potporna skrb može obuhvatiti primjenu lijekova s antiemetičkim, antidijaroičkim ili antacidnim učinkom.
English: • Burning or painful sensation in the tongue, inflammation of the digestive tract lining, excessive gas in the stomach or intestine.
Croatian: • Osjećaj pečenja ili boli u jeziku, upala sluznice probavnog sustava, prekomjerna količina plinova u želucu ili crijevima.
English: The median PFS was 11.4 months for the sunitinib arm compared to 5.5 months for the placebo arm [hazard ratio: 0.418 (95% CI: 0.263, 0.662), p-value=0.0001]; similar results were observed when derived tumour response assessments based upon application of RECIST to investigator tumour measurements were used to determine disease progression, as shown in Table 4.
Croatian: Medijan PFS-a iznosio je 11,4 mjeseca u skupini liječenoj sunitinibom u usporedbi s 5,5 mjeseci u placebo skupini [omjer hazarda: 0,418 (95% CI: 0,263; 0,662), p-vrijednost = 0,0001]; slični su rezultati uočeni kada se progresija bolesti utvrđivala pomoću procjene reakcije tumora primjenom RECIST kriterija na mjerenja tumora koja su provodili ispitivači.
English: If symptoms of pancreatitis are present, patients should have sunitinib discontinued and be provided with appropriate supportive care.
Croatian: Pojave li se simptomi pankreatitisa, treba prekinuti primjenu sunitiniba te bolesnicima osigurati odgovarajuću suportivnu skrb.
English: The most common (≥10%) reported treatment-related adverse events in patients in both groups combined were neutrophil count decreased (6 patients [20.7%]) and haemorrhage intracranial (3 patients [10.3%]) (see section 4.8).
Croatian: Najčešći (≥ 10 %) prijavljeni štetni događaji povezani s liječenjem u bolesnika u obje skupine bili su smanjenje broja neutrofila (6 bolesnika [20,7 %]) i intrakranijalno krvarenje (3 bolesnika [10,3 %]) (vidjeti dio 4.8).
English: Tell your doctor if you get tired more easily, generally feel colder than other people, or your voice deepens whilst taking Sutent.
Croatian: Obavijestite liječnika ako se tijekom liječenja lijekom Sutent brže umarate, ako primjećujete da Vam je hladnije nego drugim ljudima ili Vam se produbi glas.
English: If signs or symptoms of hepatic failure are present, sunitinib should be discontinued and appropriate supportive care should be provided (see section 4.8).
Croatian: Pojave li se znakovi ili simptomi zatajivanja jetre, treba prekinuti primjenu sunitiniba te osigurati odgovarajuću suportivnu skrb (vidjeti dio 4.8).
English: The rash may progress to widespread blistering or peeling of the skin and may be life-threatening.
Croatian: Osip može napredovati do širokorasprostranjenih mjehura ili ljuštenja kože te može biti opasan.
English: Cases of hepatic failure, some with a fatal outcome, were observed in < 1% of solid tumour patients treated with sunitinib.
Croatian: Zabilježeni su slučajevi zatajivanja jetre, neki sa smrtnim ishodom, u < 1% bolesnika sa solidnim tumorom liječenih sunitinibom.
English: Hypothyroidism was reported as an adverse reaction in 7 patients (4%) receiving sunitinib across the 2 cytokine-refractory MRCC studies; in 61 patients (16%) on sunitinib and 3 patients (< 1%) in the IFN- arm in the treatment-naïve MRCC study.
Croatian: Hipotireoza je prijavljena kao nuspojava u 7 bolesnika (4%) liječenih sunitinibom u 2 ispitivanja MRCC-a refraktornog na citokine; u 61 bolesnika (16%) koji je primao sunitinib i 3 bolesnika (< 1%) koja su primala IFN-α u ispitivanju prethodno neliječenog MRCC-a.
English: Furthermore, based on an integrated population PK analysis of pooled data from the 3 paediatric studies (2 paediatric solid tumour studies and 1 paediatric GIST study; ages: 6 years to 11 years and 12 years to 17 years), baseline body surface area (BSA) was a significant covariate on apparent clearance of sunitinib and its active metabolite.
Croatian: Nadalje, na temelju integrirane populacijske FK analize objedinjenih podataka iz 3 pedijatrijska ispitivanja (2 ispitivanja u pedijatrijskih bolesnika sa solidnim tumorima i 1 ispitivanje u pedijatrijskih bolesnika s GIST-om; dob pedijatrijskih bolesnika: od 6 do 11 godina, odnosno od 12 do 17 godina), početna površina tijela bila je značajna kovariata za prividni klirens sunitiniba i njegovog djelatnog metabolita.
English: A Phase 3, randomised, double-blind, placebo-controlled study of sunitinib was conducted in patients with GIST who were intolerant to, or had experienced disease progression during or following treatment with imatinib (median maximum daily dose 800 mg).
Croatian: Provedeno je randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje sunitiniba faze III u bolesnika s GIST-om koji nisu podnosili imatinib ili u kojih je došlo do progresije bolesti tijekom ili nakon liječenja imatinibom (medijan maksimalne dnevne doze 800 mg).
English: Dose reductions occurred in 194 patients (52%) on sunitinib and 98 patients (27%) on IFN-α.
Croatian: Doza je smanjena u 194 bolesnika (52%) liječena sunitinibom i 98 bolesnika (27%) liječenih IFN-α.
English: Experience on the use of sunitinib in paediatric patients is limited (see section 4.2).
Croatian: Iskustvo upotrebe sunitiniba u pedijatrijskih bolesnika je ograničeno (vidjeti dio 4.2).
English: Demographics were comparable between the sunitinib and placebo groups.
Croatian: Demografska obilježja bila su slična u skupinama koje su primale sunitinib odnosno placebo.
English: Epistaxis was the most common haemorrhagic adverse reaction, having been reported for approximately half of the patients with solid tumours who experienced haemorrhagic events.
Croatian: Epistaksa je bila najčešći tip krvarenja uzrokovan lijekom, a prijavljena je u približno polovice bolesnika sa solidnim tumorima u kojih je došlo do krvarenja.
English: One patient with pulmonary embolism in the cytokine-refractory MRCC study experienced dose interruption.
Croatian: U 1 bolesnika s plućnom embolijom u ispitivanju MRCC-a refraktornog na citokine došlo je do privremenog prekida primjene lijeka.
English: In this study, the median TTP was 34.0 weeks (95% CI: 22.0, 46.0).
Croatian: U ovom je ispitivanju medijan vremena do tumorske progresije bio 34,0 tjedna (95% CI: 22,0; 46,0).
English: Maternal body weight gains were reduced during gestation and lactation at ≥ 1 mg/kg/day but no maternal reproductive toxicity was observed up to 3 mg/kg/day (estimate exposure ≥ 2.3 times the AUC in patients administered the RDD).
Croatian: Pri dozi od ≥ 1 mg/kg na dan bio je smanjen prirast tjelesne mase majke tijekom gestacije i laktacije, ali maternalna reproduktivna toksičnost nije opažena pri dozama do 3 mg/kg na dan (procjenjena ekspozicija ≥ 2,3 puta od AUC-a u bolesnika koji su dobivali preporučenu dnevnu dozu).
English: The most common (≥10%) treatment-related adverse events were neutrophil count decreased (6 [20.7%] patients) and haemorrhage intracranial (3[10.3%] patients).
Croatian: Najčešći (≥ 10 %) štetni događaji povezani s liječenjem bili su smanjenje broja neutrofila (6 [20,7 %] bolesnika) i intrakranijalno krvarenje (3 [10,3 %] bolesnika)
English: In rat and monkey repeated-dose toxicity studies up to 9-months duration, the primary target organ effects were identified in the gastrointestinal tract (emesis and diarrhoea in monkeys); adrenal gland (cortical congestion and/or haemorrhage in rats and monkeys, with necrosis followed by fibrosis in rats); haemolymphopoietic system (bone morrow hypocellularity and lymphoid depletion of thymus, spleen, and lymph node); exocrine pancreas (acinar cell degranulation with single cell necrosis); salivary gland (acinar hypertrophy); bone joint (growth plate thickening); uterus (atrophy); and ovaries (decreased follicular development).
Croatian: U ispitivanjima toksičnosti ponovljenih doza na štakorima i majmunima u trajanju do 9 mjeseci, učinci na primarne ciljne organe zabilježeni su u probavnom sustavu (povraćanje i proljev kod majmuna), nadbubrežnim žlijezdama (kortikalna kongestija i/ili krvarenje kod štakora i majmuna, s nekrozom iza koje je uslijedila fibroza u štakora), hemolimfopoetskom sustavu (hipocelularnost koštane srži, limfoidna deplecija timusa, slezene i limfnih čvorova), egzokrinoj gušterači (degranulacija acinarnih stanica s nekrozom pojedinačnih stanica), žlijezdama slinovnicama (acinarna hipertrofija), zglobovima (zadebljanje epifizne ploče), uterusu (atrofija) i jajnicima (smanjen razvoj folikula).
English: In rats, embryo-foetal mortality was evident as significant reductions in the number of live foetuses, increased numbers of resorptions, increased postimplantation loss, and total litter loss in 8 of 28 pregnant females at plasma exposure levels 5.5 times the systemic exposure in humans.
Croatian: U štakora se embrio-fetalna smrtnost očitovala kao značajno smanjenje broja živih fetusa, povećan broj resorpcija, povećan gubitak ploda nakon implantacije te gubitak čitavog legla u 8 od 28 gravidnih ženki, pri ekspoziciji koncentracijama u plazmi 5,5 puta većima od sistemske izloženosti u ljudi.
English: Haemorrhage and tumour bleeding
Croatian: Krvarenje i tumorsko krvarenje
English: Serious infections, with or without neutropenia, including some with a fatal outcome, have been reported.
Croatian: Prijavljene su ozbiljne infekcije, s neutropenijom ili bez nje, od kojih su neke završile smrću.
English: nausea, vomiting, diarrhoea, constipation, abdominal pain/swelling, loss/decrease of appetite.
Croatian: mučnina, povraćanje, proljev, zatvor, bol u trbuhu/oticanje trbuha, gubitak/smanjenje teka.
English: In 1 study, hypothyroidism was reported in 15 (13.6%) patients on sunitinib and 3 (2.9%) patients on standard of care.
Croatian: U 1 ispitivanju hipotireoza je zabilježena u 15 (13,6%) bolesnika na sunitinibu i 3 (2,9%) bolesnika na standardnom liječenju.
English: If angioedema due to hypersensitivity occurs, sunitinib treatment should be interrupted and standard medical care provided (see section 4.8).
Croatian: Dođe li do angioedema zbog preosjetljivosti, treba privremeno prekinuti liječenje sunitinibom te primijeniti standardne mjere liječenja (vidjeti dio 4.8).
English: The primary efficacy endpoint was PFS. A planned interim analysis showed a statistically significant advantage for sunitinib over IFN-α, in this study, the median PFS for the sunitinib-treated group was 47.3 weeks, compared with 22.0 weeks for the IFN-α-treated group; the HR was 0.415 (95% CI: 0.320, 0.539; p-value < 0.001).
Croatian: Planirana interim analiza pokazala je statistički značajnu prednost sunitiniba nad IFN-α u ovom ispitivanju; medijan PFS-a u skupini liječenoj sunitinibom bio je 47,3 tjedna, u usporedbi s 22,0 tjedna u skupini liječenoj IFN-α; omjer hazarda je bio 0,415 (95% CI: 0,320; 0,539, p-vrijednost < 0,001).
English: The safety of continued sunitinib treatment in patients with moderate to severe proteinuria has not been systematically evaluated.
Croatian: Nije sustavno ispitivana sigurnost kontinuiranog liječenja sunitinibom u bolesnika s umjerenom do teškom proteinurijom.
English: In this study, 312 patients were randomised (2:1) to receive either 50 mg sunitinib or placebo, orally once daily on Schedule 4/2 until disease progression or withdrawal from the study for another reason (207 patients received sunitinib and 105 patients received placebo).
Croatian: U ovom je ispitivanju 312 bolesnika randomizirano (2:1) u skupine koje su primale sunitinib u dozi od 50 mg ili placebo, peroralno jedanput na dan prema shemi 4/2, do progresije bolesti ili izlaska iz ispitivanja zbog nekog drugog razloga (207 bolesnika dobivalo je sunitinib, a 105 placebo).
English: At therapeutic plasma concentrations, the maximum QTcF interval (Frederica's correction) mean change from baseline was 9 msec (90% CI: 15.1 msec).
Croatian: Pri terapijskim koncentracijama u plazmi najveća srednja vrijednost promjene QTcF-intervala (korekcija prema Fridericiji) u odnosu na početne vrijednosti iznosila je 9 ms (90% CI: 15,1 ms).
English: Sunitinib treatment in rats during organogenesis resulted in developmental effects at  5 mg/kg/day consisting of increased incidence of foetal skeletal malformations, predominantly characterised as retarded ossification of thoracic/lumbar vertebrae and occurred at plasma exposure levels 5.5 times the systemic exposure in humans.
Croatian: Primjena sunitiniba u dozi ≥5 mg/kg/dan u štakora za vrijeme organogeneze imala je za posljedicu učinke na razvoj koji su obuhvaćali povećanu incidenciju malformacija kostura fetusa, pretežno u obliku usporene osifikacije torakalnih/lumbalnih kralježaka, a javljali su se pri ekspoziciji koncentracijama u plazmi 5,5 puta većima od sistemske izloženosti u ljudi.
English: If your thyroid gland is not producing enough thyroid hormone, you may be treated with thyroid hormone replacement.
Croatian: Ako Vam štitnjača ne luči dovoljno hormona, možda ćete dobiti lijek koji će nadomjestiti hormone štitnjače.
English: None of these events in the Phase 3 studies were fatal, but rare fatal haematological events, including haemorrhage associated with thrombocytopenia and neutropenic infections, have been reported during postmarketing surveillance.
Croatian: Niti jedan od ovih događaja u ispitivanjima faze III nije bio smrtonosan, no tijekom praćenja nakon stavljanja lijeka u promet prijavljeni su rijetki smrtonosni hematološki događaji, uključujući krvarenje povezano s trombocitopenijom i neutropenijske infekcije.
English: OS (weeks)
Croatian: OS (tjedni) Interim
English: In case of symptomatic hypoglycaemia, sunitinib should be temporarily interrupted.
Croatian: U slučaju simptomatske hipoglikemije, potrebno je privremeno prekinuti primjenu sunitiniba.
English: The most common adverse reactions of any grade (experienced by patients in RCC, GIST, and pNET registrational trials) included decreased appetite, taste disturbance, hypertension, fatigue, gastrointestinal disorders (i.e. diarrhoea, nausea, stomatitis, dyspepsia, and vomiting), skin discolouration, and palmar-plantar erythrodysaesthesia syndrome.
Croatian: Najčešći štetni događaji bilo kojeg stupnja (koji su nastupili u bolesnika u registracijskim ispitivanjima u indikacijama RCC, GIST i pNET) uključivali su: smanjeni tek, poremećaj okusa, hipertenziju, umor, poremećaje probavnog sustava (tj. proljev, mučninu, stomatitis, dispepsiju i povraćanje), promjene boje kože i sindrom palmarno-plantarne eritrodizestezije.
English: Cases of serious pancreatic events, some with fatal outcome, have been reported.
Croatian: Prijavljeni su i slučajevi ozbiljnih događaja povezanih s gušteračom, od kojih su neki imali smrtni ishod.
English: As a result of the early study closure, remaining patients were unblinded and offered access to open-label sunitinib in an extension study.
Croatian: Kao rezultat ranog završetka ispitivanja, preostalim je bolesnicima otkrivena slijepa šifra terapije i ponuđeno im je otvoreno liječenje sunitinibom u produljenju ispitivanja.
English: Urinary tract infection Skin infectionse Sepsisf,*
Croatian: gljivične infekcije infekcija mokraćnog sustava kožne infekcije sepsa f,*
English: Two patients (< 1%) who received sunitinib were diagnosed with CHF.
Croatian: U 2 bolesnika (< 1%) koja su primala sunitinib dijagnosticirano je kongestivno zatajenje srca.
English: Seven hundred and fifty patients were randomised 1:1 to the treatment arms; they received treatment with either sunitinib in repeated 6-week cycles, consisting of 4 weeks of 50 mg daily oral administration followed by 2 weeks of rest (Schedule 4/2), or IFN-α, administered as a subcutaneous injection of 3 million units (MU) the first week, 6 MU the second week, and 9 MU the third week and thereafter, on 3 nonconsecutive days each week.
Croatian: U terapijske je skupine u omjeru 1:1 randomizirano 750 bolesnika; dobivali su ili sunitinib u opetovnim 6-tjednim ciklusima u kojima se 4 tjedna peroralno primjenjivala doza od 50 mg na dan, nakon čega su slijedila 2 tjedna odmora (shema 4/2), ili IFN-α u obliku supkutane injekcije u dozi od 3 milijuna jedinica (engl. million units, MU) prvi tjedan, 6 MU drugi tjedan, te 9 MU treći tjedan i dalje svaki tjedan u 3 neuzastopna dana.
English: Contact your doctor immediately if symptoms of infection occur around a skin injury, including fever, pain, redness, swelling, or drainage of pus or blood.
Croatian: Odmah se javite svom liječniku ako se pojave simptomi infekcije oko ozljede na koži, uključujući vrućicu, bol, crvenilo, oteklinu, ili izlazak gnoja ili sukrvice.
English: • Pain in the mouth, teeth and/or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth.
Croatian: • Bol u ustima, zubima i/ili čeljusti, oteklina ili ranice u usnoj šupljini, utrnulost ili osjećaj težine u čeljusti ili klimanje zuba.
English: A total of 29 patients in the sunitinib arm and 24 in the placebo arm had received no prior systemic treatment; among these patients, the hazard ratio for PFS was 0.365 (95% CI: 0.156, 0.857), p=0.0156.
Croatian: Ukupno 29 bolesnika u skupini liječenoj sunitinibom te 24 bolesnika u skupini koja je primala placebo nije prethodno primalo sustavnu terapiju; među tim je bolesnicima omjer hazrada za PFS iznosio 0,365 (95% CI: 0,156; 0,857), p = 0,0156.
English: − GIST or MRCC: the usual dose is 50 mg once daily taken for 28 days (4 weeks), followed by 14 days (2 weeks) of rest (no medicine), in 6-week cycles.
Croatian: Ako se liječite od: - GIST-a ili MRCC: uobičajena doza je 50 mg jedanput na dan tijekom 28 dana (4 tjedna), nakon čega slijedi 14 dana (2 tjedna) odmora (bez uzimanja lijeka), tako da cijeli ciklus traje 6 tjedana.
English: Cases of pyoderma gangrenosum, generally reversible after discontinuation of sunitinib, have been reported (see also section 4.4).
Croatian: Prijavljeni su slučajevi gangrenozne piodermije, reverzibilne općenito nakon prekida terapije sunitinibom (vidjeti i dio 4.4).
English: Tell your doctor if you have any of these symptoms or a serious bleeding problem during treatment with Sutent: painful, swollen stomach (abdomen); vomiting blood; black, sticky stools; bloody urine; headache or change in your mental status; coughing up of blood or bloody sputum from the lungs or airway.
Croatian: Obavijestite liječnika ako tijekom liječenja lijekom Sutent nastupi ozbiljno krvarenje, ili se pojavi neki od sljedećih simptoma: bolan i natečen trbuh (abdomen), povraćanje krvi, crna ljepljiva stolica, krv u mokraći, glavobolja ili promjena psihičkog stanja, iskašljavanje krvi ili krvavi iskašljaj iz pluća ili dišnih puteva.
English: Patients should be advised that depigmentation of the hair or skin may occur during treatment with sunitinib.
Croatian: Bolesnike treba upozoriti da tijekom liječenja sunitinibom može doći do depigmentacije kose ili kože.
English: In clinical trials, decreases in left ventricular ejection fraction (LVEF) of  20% and below the lower limit of normal were reported in approximately 2% of sunitinib-treated GIST patients, 4% of cytokine-refractory MRCC patients, and 2% of placebo-treated GIST patients.
Croatian: U kliničkim ispitivanjima, smanjenje istisne frakcije lijeve klijetke (engl. left ventricular ejection fraction, LVEF) za ≥ 20% i ispod donje granice normalnih vrijednosti zabilježeno je u približno 2% bolesnika s GIST-om liječenih sunitinibom, 4% bolesnika s MRCC-om refraktornim na citokine te u 2% bolesnika s GIST-om koji su primali placebo.
English: CYP3A4 inhibitors/inducers
Croatian: Inhibitori/induktori CYP3A4
English: Sunitinib was not permanently discontinued in any of these patients.
Croatian: Niti jednom bolesniku liječenje sunitinibom nije trajno obustavljeno.
English: Administration of sunitinib with potent CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital or herbal preparations containing St. John's Wort/Hypericum perforatum) may decrease sunitinib concentrations.
Croatian: Primjena sunitiniba sa snažnim induktorima CYP3A4 (npr. deksametazonom, fenitoinom, karbamazepinom, rifampicinom, fenobarbitalom ili biljnim lijekovima koji sadrže gospinu travu/Hypericum perforatum) može sniziti koncentracije sunitiniba.
English: Tumour destruction leading to hole in the intestine.
Croatian: Tumorsko oštećenje tkiva koje dovodi do puknuća stijenke crijeva.